Biodesix announces new clinical utility evidence for the nodify xl2® nodule risk assessment test to be presented at ats 2022 international conference

Boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, announces new clinical utility data highlighting the impact of the nodify xl2 risk assessment test on clinical management decisions in patients with lung nodules will be presented at the american thoracic society (ats) 2022 international conference. the meeting will take place may 13-18, 2022, in san francisco, california. data from the abstract titled
BDSX Ratings Summary
BDSX Quant Ranking